ID   K1C10_HUMAN             Reviewed;         584 AA.
AC   P13645; Q14664; Q8N175;
DT   01-JAN-1990, integrated into UniProtKB/Swiss-Prot.
DT   24-NOV-2009, sequence version 6.
DT   28-JUN-2023, entry version 225.
DE   RecName: Full=Keratin, type I cytoskeletal 10;
DE   AltName: Full=Cytokeratin-10;
DE            Short=CK-10;
DE   AltName: Full=Keratin-10;
DE            Short=K10;
GN   Name=KRT10; Synonyms=KPP;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS SER-101 AND TYR-487.
RC   TISSUE=Foreskin;
RX   PubMed=2459124; DOI=10.1016/s0021-9258(19)37628-8;
RA   Zhou X.M., Idler W.W., Steven A.C., Roop D.R., Steinert P.M.;
RT   "The complete sequence of the human intermediate filament chain keratin 10.
RT   Subdomainal divisions and model for folding of end domain sequences.";
RL   J. Biol. Chem. 263:15584-15589(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT TYR-487.
RX   PubMed=2464696; DOI=10.1016/0022-2836(88)90045-9;
RA   Rieger M., Franke W.W.;
RT   "Identification of an orthologous mammalian cytokeratin gene. High degree
RT   of intron sequence conservation during evolution of human cytokeratin 10.";
RL   J. Mol. Biol. 204:841-856(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S.,
RA   Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E.,
RA   Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K.,
RA   LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J.,
RA   Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A.,
RA   Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K.,
RA   Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in the
RT   human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS SER-101 AND TYR-487.
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 130-584, AND VARIANT TYR-487.
RX   PubMed=2448602; DOI=10.1007/bf00444680;
RA   Darmon M.Y., Semat A., Darmon M.C., Vasseur M.;
RT   "Sequence of a cDNA encoding human keratin No 10 selected according to
RT   structural homologies of keratins and their tissue-specific expression.";
RL   Mol. Biol. Rep. 12:277-283(1987).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 147-161, AND VARIANTS EHK HIS-156 AND
RP   ASN-160.
RX   PubMed=7507150; DOI=10.1111/1523-1747.ep12371723;
RA   Rothnagel J.A., Longley M.A., Holder R.A., Kuster W., Roop D.R.;
RT   "Prenatal diagnosis of epidermolytic hyperkeratosis by direct gene
RT   sequencing.";
RL   J. Invest. Dermatol. 102:13-16(1994).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 147-161, AND VARIANT EHK CYS-156.
RA   Rothnagel J.J., Dominey A., Fisher M., Axtell S., Pittelkow M.,
RA   Anton-Lamprecht I., Hohl D., Roop D.;
RT   "Identification of mutational hot spots in the suprabasal keratin genes
RT   from patients with epidermolytic hyperkeratosis.";
RL   Submitted (JUN-1993) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 197-584.
RX   PubMed=1378806; DOI=10.1016/0378-1119(92)90521-p;
RA   Tkachenko A.V., Buchman V.L., Bliskovsky V.V., Shvets Y.P., Kisselev L.L.;
RT   "Exons I and VII of the gene (Ker10) encoding human keratin 10 undergo
RT   structural rearrangements within repeats.";
RL   Gene 116:245-251(1992).
RN   [9]
RP   PROTEIN SEQUENCE OF 180-184 AND 568-580.
RC   TISSUE=Keratinocyte;
RX   PubMed=1286667; DOI=10.1002/elps.11501301199;
RA   Rasmussen H.H., van Damme J., Puype M., Gesser B., Celis J.E.,
RA   Vandekerckhove J.;
RT   "Microsequences of 145 proteins recorded in the two-dimensional gel protein
RT   database of normal human epidermal keratinocytes.";
RL   Electrophoresis 13:960-969(1992).
RN   [10]
RP   INTERACTION WITH STAPHYLOCOCCUS AUREUS CLFB (MICROBIAL INFECTION),
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=12427098; DOI=10.1046/j.1462-5822.2002.00231.x;
RA   O'Brien L.M., Walsh E.J., Massey R.C., Peacock S.J., Foster T.J.;
RT   "Staphylococcus aureus clumping factor B (ClfB) promotes adherence to human
RT   type I cytokeratin 10: implications for nasal colonization.";
RL   Cell. Microbiol. 4:759-770(2002).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Lymphoblast;
RX   PubMed=14654843; DOI=10.1038/nature02166;
RA   Andersen J.S., Wilkinson C.J., Mayor T., Mortensen P., Nigg E.A., Mann M.;
RT   "Proteomic characterization of the human centrosome by protein correlation
RT   profiling.";
RL   Nature 426:570-574(2003).
RN   [12]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH STAPHYLOCOCCUS AUREUS
RP   CLFB (MICROBIAL INFECTION).
RX   PubMed=15385531; DOI=10.1074/jbc.m408713200;
RA   Walsh E.J., O'Brien L.M., Liang X., Hoeoek M., Foster T.J.;
RT   "Clumping factor B, a fibrinogen-binding MSCRAMM (microbial surface
RT   components recognizing adhesive matrix molecules) adhesin of Staphylococcus
RT   aureus, also binds to the tail region of type I cytokeratin 10.";
RL   J. Biol. Chem. 279:50691-50699(2004).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-16 AND SER-42, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [14]
RP   FUNCTION (MICROBIAL INFECTION), INTERACTION WITH S.PNEUMONIAE PSRP
RP   (MICROBIAL INFECTION), SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=19627498; DOI=10.1111/j.1365-2958.2009.06796.x;
RA   Shivshankar P., Sanchez C., Rose L.F., Orihuela C.J.;
RT   "The Streptococcus pneumoniae adhesin PsrP binds to keratin 10 on lung
RT   cells.";
RL   Mol. Microbiol. 73:663-679(2009).
RN   [15]
RP   INVOLVEMENT IN IWC.
RX   PubMed=20798280; DOI=10.1126/science.1192280;
RA   Choate K.A., Lu Y., Zhou J., Choi M., Elias P.M., Farhi A.,
RA   Nelson-Williams C., Crumrine D., Williams M.L., Nopper A.J., Bree A.,
RA   Milstone L.M., Lifton R.P.;
RT   "Mitotic recombination in patients with ichthyosis causes reversion of
RT   dominant mutations in KRT10.";
RL   Science 330:94-97(2010).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14; SER-16; SER-42; SER-53;
RP   SER-56 AND SER-170, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [18]
RP   IDENTIFICATION IN A COMPLEX WITH KRT1, AND INTERACTION WITH KRT1 AND PLEC.
RX   PubMed=24940650; DOI=10.1038/jid.2014.255;
RA   Bouameur J.E., Favre B., Fontao L., Lingasamy P., Begre N., Borradori L.;
RT   "Interaction of plectin with keratins 5 and 14: dependence on several
RT   plectin domains and keratin quaternary structure.";
RL   J. Invest. Dermatol. 134:2776-2783(2014).
RN   [19]
RP   INTERACTION WITH S.PNEUMONIAE PSRP (MICROBIAL INFECTION).
RX   PubMed=24430336; DOI=10.1098/rsob.130090;
RA   Schulte T., Lofling J., Mikaelsson C., Kikhney A., Hentrich K.,
RA   Diamante A., Ebel C., Normark S., Svergun D., Henriques-Normark B.,
RA   Achour A.;
RT   "The basic keratin 10-binding domain of the virulence-associated
RT   pneumococcal serine-rich protein PsrP adopts a novel MSCRAMM fold.";
RL   Open Biol. 4:130090-130090(2014).
RN   [20]
RP   ERRATUM OF PUBMED:24430336.
RX   DOI=10.1098/rsob.140172;
RA   Schulte T., Lofling J., Mikaelsson C., Kikhney A., Hentrich K.,
RA   Diamante A., Ebel C., Normark S., Svergun D., Henriques-Normark B.,
RA   Achour A.;
RL   Open Biol. 4:140172-140172(2014).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [23]
RP   SUBCELLULAR LOCATION, AND INDUCTION BY ATRA.
RX   PubMed=32179842; DOI=10.1038/s41598-020-61640-9;
RA   Aldehlawi H., Usman S., Lalli A., Ahmad F., Williams G., Teh M.T.,
RA   Waseem A.;
RT   "Serum lipids, retinoic acid and phenol red differentially regulate
RT   expression of keratins K1, K10 and K2 in cultured keratinocytes.";
RL   Sci. Rep. 10:4829-4829(2020).
RN   [24] {ECO:0007744|PDB:3ASW}
RP   X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 473-487 IN COMPLEX WITH
RP   STAPHYLOCOCCUS AUREUS CLFB.
RA   Ganesh V.K., Barbu E.M., Deivanayagam C.C.S., Le B., Anderson A.,
RA   Matsuka Y., Lin S.L., Foster T.J., Narayana S.L., Hook M.;
RT   "Structural and biochemical characterization of ClfB:ligand interactions.";
RL   Submitted (DEC-2010) to the PDB data bank.
RN   [25] {ECO:0007744|PDB:4F1Z}
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 499-512 IN COMPLEX WITH
RP   STAPHYLOCOCCUS AUREUS CLFB, AND INTERACTION WITH STAPHYLOCOCCUS AUREUS
RP   CLFB.
RX   PubMed=22719251; DOI=10.1371/journal.ppat.1002751;
RA   Xiang H., Feng Y., Wang J., Liu B., Chen Y., Liu L., Deng X., Yang M.;
RT   "Crystal structures reveal the multi-ligand binding mechanism of
RT   Staphylococcus aureus ClfB.";
RL   PLoS Pathog. 8:e1002751-e1002751(2012).
RN   [26] {ECO:0007744|PDB:4ZRY}
RP   X-RAY CRYSTALLOGRAPHY (3.30 ANGSTROMS) OF 337-456 IN COMPLEX WITH KRT1,
RP   SUBUNIT, AND DISULFIDE BONDS.
RX   PubMed=27595935; DOI=10.1016/j.jid.2016.08.018;
RA   Bunick C.G., Milstone L.M.;
RT   "The X-Ray Crystal Structure of the Keratin1-Keratin 10 Helix 2B
RT   Heterodimer Reveals Molecular Surface Properties and Biochemical Insights
RT   into Human Skin Disease.";
RL   J. Invest. Dermatol. 137:142-150(2017).
RN   [27]
RP   VARIANT EHK HIS-156.
RX   PubMed=1381287; DOI=10.1016/0092-8674(92)90314-3;
RA   Cheng J., Syder A.J., Yu Q.-C., Letai A., Paller A.S., Fuchs E.;
RT   "The genetic basis of epidermolytic hyperkeratosis: a disorder of
RT   differentiation-specific epidermal keratin genes.";
RL   Cell 70:811-819(1992).
RN   [28]
RP   VARIANTS.
RX   PubMed=1371013; DOI=10.1073/pnas.89.3.910;
RA   Korge B.P., Gan S.-Q., McBridge O.W., Mischke D., Steinert P.M.;
RT   "Extensive size polymorphism of the human keratin 10 chain resides in the
RT   C-terminal V2 subdomain due to variable numbers and sizes of glycine
RT   loops.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:910-914(1992).
RN   [29]
RP   VARIANTS EHK HIS-156 AND SER-161.
RX   PubMed=1380725; DOI=10.1126/science.257.5073.1128;
RA   Rothnagel J.A., Dominey A.M., Dempsey L.D., Longley M.A., Greenhalgh D.A.,
RA   Gagne T.A., Huber M., Frenk E., Hohl D., Roop D.R.;
RT   "Mutations in the rod domains of keratins 1 and 10 in epidermolytic
RT   hyperkeratosis.";
RL   Science 257:1128-1130(1992).
RN   [30]
RP   VARIANTS EHK HIS-154; CYS-156; HIS-156; ASP-160 AND GLN-442.
RX   PubMed=7508181;
RA   Chipev C.C., Yang J.-M., Digiovanna J.J., Steinert P.M., Marekov L.,
RA   Compton J.G., Bale S.J.;
RT   "Preferential sites in keratin 10 that are mutated in epidermolytic
RT   hyperkeratosis.";
RL   Am. J. Hum. Genet. 54:179-190(1994).
RN   [31]
RP   VARIANTS EHK ARG-150; CYS-156 AND GLU-439, AND VARIANT SER-126.
RX   PubMed=7512983; DOI=10.1172/jci117132;
RA   Syder A.J., Yu Q.-C., Paller A.S., Giudice G., Pearson R., Fuchs E.;
RT   "Genetic mutations in the K1 and K10 genes of patients with epidermolytic
RT   hyperkeratosis. Correlation between location and disease severity.";
RL   J. Clin. Invest. 93:1533-1542(1994).
RN   [32]
RP   VARIANTS EHK PRO-156 AND SER-156.
RX   PubMed=7507152; DOI=10.1111/1523-1747.ep12371726;
RA   McLean W.H.I., Eady R.A.J., Dopping-Hepenstal P.J.C., McMillan J.R.,
RA   Leigh I.M., Navsaria H.A., Higgins C., Harper J.I., Paige D.G.,
RA   Morley S.M.;
RT   "Mutations in the rod 1A domain of keratins 1 and 10 in bullous congenital
RT   ichthyosiform erythroderma (BCIE).";
RL   J. Invest. Dermatol. 102:24-30(1994).
RN   [33]
RP   VARIANT EHK THR-150.
RX   PubMed=7526210; DOI=10.1056/nejm199411243312103;
RA   Paller A.S., Syder A.J., Chan Y.-M., Yu Q.-C., Hutton M.E., Tadini G.,
RA   Fuchs E.;
RT   "Genetic and clinical mosaicism in a type of epidermal nevus.";
RL   N. Engl. J. Med. 331:1408-1415(1994).
RN   [34]
RP   VARIANT AEI1 GLU-422.
RX   PubMed=9036939; DOI=10.1111/1523-1747.ep12286491;
RA   Joh G.-Y., Traupe H., Metze D., Nashan D., Huber M., Hohl D., Longley M.A.,
RA   Rothnagel J.A., Roop D.R.;
RT   "A novel dinucleotide mutation in keratin 10 in the annular epidermolytic
RT   ichthyosis variant of bullous congenital ichthyosiform erythroderma.";
RL   J. Invest. Dermatol. 108:357-361(1997).
RN   [35]
RP   VARIANT AEI1 THR-446.
RX   PubMed=9856845; DOI=10.1046/j.1523-1747.1998.00451.x;
RA   Suga Y., Duncan K.O., Heald P.W., Roop D.R.;
RT   "A novel helix termination mutation in keratin 10 in annular epidermolytic
RT   ichthyosis, a variant of bullous congenital ichthyosiform erythroderma.";
RL   J. Invest. Dermatol. 111:1220-1223(1998).
RN   [36]
RP   VARIANT EHK SER-160.
RX   PubMed=10201536; DOI=10.1046/j.1523-1747.1999.00557.x;
RA   Arin M.J., Longley M.A., Anton-Lamprecht I., Kurze G., Huber M., Hohl D.,
RA   Rothnagel J.A., Roop D.R.;
RT   "A novel substitution in keratin 10 in epidermolytic hyperkeratosis.";
RL   J. Invest. Dermatol. 112:506-508(1999).
RN   [37]
RP   VARIANTS EHK ARG-150; THR-150; CYS-156; HIS-156 AND CYS-449.
RX   PubMed=21271994; DOI=10.1111/j.1365-2133.2010.10096.x;
RA   Arin M.J., Oji V., Emmert S., Hausser I., Traupe H., Krieg T., Grimberg G.;
RT   "Expanding the keratin mutation database: novel and recurrent mutations and
RT   genotype-phenotype correlations in 28 patients with epidermolytic
RT   ichthyosis.";
RL   Br. J. Dermatol. 164:442-447(2011).
RN   [38]
RP   INVOLVEMENT IN IHL, AND VARIANT IHL PRO-435.
RX   PubMed=27212473; DOI=10.1684/ejd.2016.2808;
RA   Wang W.H., Zhang L., Li L.F., Sun T.T.;
RT   "Ichthyosis hystrix Lambert type and Curth-Macklin type are a single entity
RT   with affected (KRT1 mutation) or unaffected (KRT10 mutation) palms and
RT   soles?";
RL   Eur. J. Dermatol. 26:493-495(2016).
CC   -!- FUNCTION: Plays a role in the establishment of the epidermal barrier on
CC       plantar skin (By similarity). Involved in the maintenance of cell layer
CC       development and keratin filament bundles in suprabasal cells of the
CC       epithelium (By similarity). {ECO:0000250|UniProtKB:P02535}.
CC   -!- FUNCTION: (Microbial infection) Acts as a mediator of S.aureus
CC       adherence to desquamated nasal epithelial cells via clfB, and hence may
CC       play a role in nasal colonization. {ECO:0000269|PubMed:15385531}.
CC   -!- FUNCTION: (Microbial infection) Binds S.pneumoniae PsrP, mediating
CC       adherence of the bacteria to lung cell lines. Reduction of levels of
CC       KRT10 keratin decrease adherence, overexpression increases adherence.
CC       Neither protein has to be glycosylated for the interaction to occur.
CC       {ECO:0000269|PubMed:19627498}.
CC   -!- SUBUNIT: Heterotetramer of two type I and two type II keratins.
CC       Heterodimer with KRT1 (PubMed:24940650, PubMed:27595935). Two
CC       heterodimers of KRT1 and KRT10 form a heterotetramer (PubMed:27595935).
CC       The KRT10 subunit in the heterotetramer is probably disulfide-linked
CC       (PubMed:27595935). Interacts with PLEC isoform 1C, when in a
CC       heterodimer with KRT1 (PubMed:24940650). {ECO:0000269|PubMed:24940650,
CC       ECO:0000269|PubMed:27595935, ECO:0000303|PubMed:27595935}.
CC   -!- SUBUNIT: (Microbial infection) Interacts (via C-terminal tail domain)
CC       with the S.aureus clumping factor, clfB; this interaction probably
CC       mediates S.aureus attachment to the keratinized squamous epithelial
CC       cells from the nasal cavity. {ECO:0000269|PubMed:12427098,
CC       ECO:0000269|PubMed:15385531, ECO:0000269|PubMed:22719251}.
CC   -!- SUBUNIT: (Microbial infection) Interacts (via the C-terminal tail
CC       domain) with S.pneumoniae serine-rich repeat protein PsrP; this
CC       interaction probably mediates S.pneumoniae adherence to lung tissue and
CC       subsequent pathogenesis. Neither protein has to be glycosylated for the
CC       interaction to occur. {ECO:0000269|PubMed:19627498,
CC       ECO:0000269|PubMed:24430336}.
CC   -!- INTERACTION:
CC       P13645; P04264: KRT1; NbExp=5; IntAct=EBI-465144, EBI-298429;
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space
CC       {ECO:0000269|PubMed:12427098}. Cell surface
CC       {ECO:0000269|PubMed:19627498}. Cytoplasm {ECO:0000269|PubMed:32179842}.
CC   -!- TISSUE SPECIFICITY: Seen in all suprabasal cell layers including
CC       stratum corneum. Expressed on the surface of lung cell lines
CC       (PubMed:19627498). Localized on the surface of desquamated nasal
CC       epithelial cells (at protein level) (PubMed:12427098).
CC       {ECO:0000269|PubMed:12427098, ECO:0000269|PubMed:19627498}.
CC   -!- INDUCTION: Repressed in keratinocytes by all-trans retinoic acid
CC       (ATRA), via reduction of mRNA stability. {ECO:0000269|PubMed:32179842}.
CC   -!- POLYMORPHISM: A number of alleles are known that mainly differ in the
CC       Gly-rich region (positions 490-560).
CC   -!- DISEASE: Epidermolytic hyperkeratosis (EHK) [MIM:113800]: An autosomal
CC       dominant skin disorder characterized by widespread blistering and an
CC       ichthyotic erythroderma at birth that persist into adulthood.
CC       Histologically there is a diffuse epidermolytic degeneration in the
CC       lower spinous layer of the epidermis. Within a few weeks from birth,
CC       erythroderma and blister formation diminish and hyperkeratoses develop.
CC       {ECO:0000269|PubMed:10201536, ECO:0000269|PubMed:1380725,
CC       ECO:0000269|PubMed:1381287, ECO:0000269|PubMed:21271994,
CC       ECO:0000269|PubMed:7507150, ECO:0000269|PubMed:7507152,
CC       ECO:0000269|PubMed:7508181, ECO:0000269|PubMed:7512983,
CC       ECO:0000269|PubMed:7526210, ECO:0000269|Ref.7}. Note=The disease is
CC       caused by variants affecting the gene represented in this entry.
CC   -!- DISEASE: Ichthyosis, annular epidermolytic, 1 (AEI1) [MIM:607602]: A
CC       form of annular epidermolytic ichthyosis, an autosomal dominant skin
CC       disorder characterized by polycyclic, migratory erythematous and scaly
CC       plaques. AEI1 is characterized by the development of widespread
CC       erythematous blistering in the neonatal period or early childhood that
CC       subsides over time. {ECO:0000269|PubMed:9036939,
CC       ECO:0000269|PubMed:9856845}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Ichthyosis with confetti (IWC) [MIM:609165]: An autosomal
CC       dominant, rare skin condition characterized by slowly enlarging islands
CC       of normal skin surrounded by erythematous ichthyotic patches in a
CC       reticulated pattern. The condition starts in infancy as a lamellar
CC       ichthyosis, with small islands of normal skin resembling confetti
CC       appearing in late childhood and at puberty. Histopathologic findings
CC       include band-like parakeratosis, psoriasiform acanthosis, and
CC       vacuolization of keratinocytes with binucleated cells in the upper
CC       epidermis, sometimes associated with amyloid deposition in the dermis.
CC       Ultrastructural abnormalities include perinuclear shells formed from a
CC       network of fine filaments in the upper epidermis.
CC       {ECO:0000269|PubMed:20798280}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Ichthyosis histrix, Lambert type (IHL) [MIM:146600]: An
CC       autosomal dominant form of ichthyosis, a disorder of keratinization
CC       with abnormal differentiation and desquamation of the epidermis,
CC       resulting in abnormal skin scaling. IHL is characterized by normal skin
CC       at birth that develops striking spiny hyperkeratotic lesions within a
CC       few months. There is sparing of the face, palms, and soles, and
CC       affected individuals do not experience blistering.
CC       {ECO:0000269|PubMed:27212473}. Note=The disease may be caused by
CC       variants affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: There are two types of cytoskeletal and microfibrillar
CC       keratin: I (acidic; 40-55 kDa) and II (neutral to basic; 56-70 kDa).
CC   -!- SIMILARITY: Belongs to the intermediate filament family.
CC       {ECO:0000255|PROSITE-ProRule:PRU01188}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA59468.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Human Intermediate Filament Mutation Database;
CC       URL="http://www.interfil.org";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Keratin-10 entry;
CC       URL="https://en.wikipedia.org/wiki/Keratin_10";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; J04029; AAA60544.1; -; mRNA.
DR   EMBL; X14487; CAA32649.1; -; Genomic_DNA.
DR   EMBL; AC090283; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; BC034697; AAH34697.1; -; mRNA.
DR   EMBL; M19156; AAA59468.1; ALT_INIT; mRNA.
DR   EMBL; L20218; AAB59438.1; -; Genomic_DNA.
DR   EMBL; L20219; AAB59439.1; -; Genomic_DNA.
DR   EMBL; M77663; AAA59199.1; -; mRNA.
DR   CCDS; CCDS11377.1; -.
DR   PIR; A31994; A31994.
DR   PIR; S02158; KRHU0.
DR   RefSeq; NP_000412.3; NM_000421.3.
DR   PDB; 3ASW; X-ray; 2.60 A; B=473-487.
DR   PDB; 4F1Z; X-ray; 2.30 A; Q=499-512.
DR   PDB; 4ZRY; X-ray; 3.30 A; A=337-456.
DR   PDB; 6E2J; X-ray; 2.39 A; B=195-296.
DR   PDB; 6EC0; X-ray; 2.98 A; B=195-296.
DR   PDB; 6UUI; X-ray; 2.07 A; X=337-456.
DR   PDBsum; 3ASW; -.
DR   PDBsum; 4F1Z; -.
DR   PDBsum; 4ZRY; -.
DR   PDBsum; 6E2J; -.
DR   PDBsum; 6EC0; -.
DR   PDBsum; 6UUI; -.
DR   AlphaFoldDB; P13645; -.
DR   SMR; P13645; -.
DR   BioGRID; 110056; 158.
DR   ComplexPortal; CPX-5662; Keratin-1 - Keratin-10 dimer complex.
DR   IntAct; P13645; 43.
DR   MINT; P13645; -.
DR   STRING; 9606.ENSP00000269576; -.
DR   DrugBank; DB09130; Copper.
DR   DrugBank; DB01593; Zinc.
DR   DrugBank; DB14487; Zinc acetate.
DR   GlyCosmos; P13645; 2 sites, 1 glycan.
DR   GlyGen; P13645; 5 sites, 2 O-linked glycans (5 sites).
DR   iPTMnet; P13645; -.
DR   PhosphoSitePlus; P13645; -.
DR   SwissPalm; P13645; -.
DR   BioMuta; KRT10; -.
DR   DMDM; 269849769; -.
DR   REPRODUCTION-2DPAGE; P13645; -.
DR   SWISS-2DPAGE; P13645; -.
DR   CPTAC; CPTAC-5854; -.
DR   CPTAC; CPTAC-5879; -.
DR   CPTAC; non-CPTAC-2680; -.
DR   EPD; P13645; -.
DR   jPOST; P13645; -.
DR   MassIVE; P13645; -.
DR   PaxDb; P13645; -.
DR   PeptideAtlas; P13645; -.
DR   PRIDE; P13645; -.
DR   ProteomicsDB; 52950; -.
DR   TopDownProteomics; P13645; -.
DR   Antibodypedia; 1606; 1622 antibodies from 45 providers.
DR   DNASU; 3858; -.
DR   Ensembl; ENST00000269576.6; ENSP00000269576.5; ENSG00000186395.9.
DR   GeneID; 3858; -.
DR   KEGG; hsa:3858; -.
DR   MANE-Select; ENST00000269576.6; ENSP00000269576.5; NM_000421.5; NP_000412.4.
DR   UCSC; uc002hvi.4; human.
DR   AGR; HGNC:6413; -.
DR   CTD; 3858; -.
DR   DisGeNET; 3858; -.
DR   GeneCards; KRT10; -.
DR   HGNC; HGNC:6413; KRT10.
DR   HPA; ENSG00000186395; Tissue enriched (skin).
DR   MalaCards; KRT10; -.
DR   MIM; 113800; phenotype.
DR   MIM; 146600; phenotype.
DR   MIM; 148080; gene.
DR   MIM; 607602; phenotype.
DR   MIM; 609165; phenotype.
DR   neXtProt; NX_P13645; -.
DR   OpenTargets; ENSG00000186395; -.
DR   Orphanet; 281139; Annular epidermolytic ichthyosis.
DR   Orphanet; 312; Autosomal dominant epidermolytic ichthyosis.
DR   Orphanet; 512103; Autosomal recessive epidermolytic ichthyosis.
DR   Orphanet; 281190; Congenital reticular ichthyosiform erythroderma.
DR   PharmGKB; PA30200; -.
DR   VEuPathDB; HostDB:ENSG00000186395; -.
DR   eggNOG; ENOG502QV0B; Eukaryota.
DR   GeneTree; ENSGT00940000160849; -.
DR   HOGENOM; CLU_012560_8_3_1; -.
DR   InParanoid; P13645; -.
DR   OMA; QGQPRDY; -.
DR   OrthoDB; 4640531at2759; -.
DR   PhylomeDB; P13645; -.
DR   TreeFam; TF332742; -.
DR   PathwayCommons; P13645; -.
DR   Reactome; R-HSA-6805567; Keratinization.
DR   Reactome; R-HSA-6809371; Formation of the cornified envelope.
DR   SignaLink; P13645; -.
DR   SIGNOR; P13645; -.
DR   BioGRID-ORCS; 3858; 258 hits in 1164 CRISPR screens.
DR   ChiTaRS; KRT10; human.
DR   GeneWiki; Keratin_10; -.
DR   GenomeRNAi; 3858; -.
DR   Pharos; P13645; Tbio.
DR   PRO; PR:P13645; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; P13645; protein.
DR   Bgee; ENSG00000186395; Expressed in upper leg skin and 205 other tissues.
DR   ExpressionAtlas; P13645; baseline and differential.
DR   Genevisible; P13645; HS.
DR   GO; GO:0009986; C:cell surface; IEA:UniProtKB-SubCell.
DR   GO; GO:0001533; C:cornified envelope; IDA:CAFA.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; HDA:UniProtKB.
DR   GO; GO:0005882; C:intermediate filament; NAS:UniProtKB.
DR   GO; GO:0045095; C:keratin filament; IPI:ComplexPortal.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; HDA:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IDA:UniProtKB.
DR   GO; GO:0030280; F:structural constituent of skin epidermis; IDA:CAFA.
DR   GO; GO:0030855; P:epithelial cell differentiation; IBA:GO_Central.
DR   GO; GO:0045109; P:intermediate filament organization; IBA:GO_Central.
DR   GO; GO:0030216; P:keratinocyte differentiation; IEP:UniProtKB.
DR   GO; GO:0018149; P:peptide cross-linking; IDA:CAFA.
DR   GO; GO:0045684; P:positive regulation of epidermis development; ISS:UniProtKB.
DR   GO; GO:0051290; P:protein heterotetramerization; IDA:UniProtKB.
DR   Gene3D; 1.20.5.170; -; 1.
DR   Gene3D; 1.20.5.500; Single helix bin; 1.
DR   Gene3D; 1.20.5.1160; Vasodilator-stimulated phosphoprotein; 1.
DR   InterPro; IPR018039; IF_conserved.
DR   InterPro; IPR039008; IF_rod_dom.
DR   InterPro; IPR002957; Keratin_I.
DR   PANTHER; PTHR23239; INTERMEDIATE FILAMENT; 1.
DR   PANTHER; PTHR23239:SF137; KERATIN, TYPE I CYTOSKELETAL 10; 1.
DR   Pfam; PF00038; Filament; 1.
DR   PRINTS; PR01248; TYPE1KERATIN.
DR   SMART; SM01391; Filament; 1.
DR   SUPFAM; SSF64593; Intermediate filament protein, coiled coil region; 2.
DR   SUPFAM; SSF46579; Prefoldin; 1.
DR   PROSITE; PS00226; IF_ROD_1; 1.
DR   PROSITE; PS51842; IF_ROD_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Coiled coil; Cytoplasm; Direct protein sequencing;
KW   Disease variant; Disulfide bond; Ichthyosis; Intermediate filament;
KW   Keratin; Phosphoprotein; Reference proteome; Secreted.
FT   CHAIN           1..584
FT                   /note="Keratin, type I cytoskeletal 10"
FT                   /id="PRO_0000063642"
FT   DOMAIN          146..460
FT                   /note="IF rod"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01188"
FT   REGION          1..145
FT                   /note="Head"
FT   REGION          1..24
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          146..181
FT                   /note="Coil 1A"
FT   REGION          182..202
FT                   /note="Linker 1"
FT   REGION          203..294
FT                   /note="Coil 1B"
FT   REGION          295..317
FT                   /note="Linker 12"
FT   REGION          318..456
FT                   /note="Coil 2"
FT   REGION          453..584
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          457..584
FT                   /note="Tail"
FT   COMPBIAS        1..15
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        510..532
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        546..584
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         14
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         16
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         42
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         53
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         56
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         170
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   DISULFID        401
FT                   /note="Interchain"
FT                   /evidence="ECO:0000305|PubMed:27595935,
FT                   ECO:0007744|PDB:4ZRY"
FT   VARIANT         101
FT                   /note="I -> S (in dbSNP:rs4261597)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:2459124"
FT                   /id="VAR_058202"
FT   VARIANT         126
FT                   /note="G -> S (in dbSNP:rs77919366)"
FT                   /evidence="ECO:0000269|PubMed:21271994,
FT                   ECO:0000269|PubMed:7512983"
FT                   /id="VAR_010505"
FT   VARIANT         150
FT                   /note="M -> R (in EHK; dbSNP:rs58901407)"
FT                   /evidence="ECO:0000269|PubMed:21271994,
FT                   ECO:0000269|PubMed:7512983"
FT                   /id="VAR_010506"
FT   VARIANT         150
FT                   /note="M -> T (in EHK; also found in a patient with
FT                   hyperkeratotic epidermal nevi due to genetic mosaicism;
FT                   dbSNP:rs58901407)"
FT                   /evidence="ECO:0000269|PubMed:21271994,
FT                   ECO:0000269|PubMed:7526210"
FT                   /id="VAR_010507"
FT   VARIANT         154
FT                   /note="N -> H (in EHK; dbSNP:rs57784225)"
FT                   /evidence="ECO:0000269|PubMed:7508181"
FT                   /id="VAR_003826"
FT   VARIANT         156
FT                   /note="R -> C (in EHK; dbSNP:rs58852768)"
FT                   /evidence="ECO:0000269|PubMed:21271994,
FT                   ECO:0000269|PubMed:7508181, ECO:0000269|PubMed:7512983,
FT                   ECO:0000269|Ref.7"
FT                   /id="VAR_003828"
FT   VARIANT         156
FT                   /note="R -> H (in EHK; dbSNP:rs58075662)"
FT                   /evidence="ECO:0000269|PubMed:1380725,
FT                   ECO:0000269|PubMed:1381287, ECO:0000269|PubMed:21271994,
FT                   ECO:0000269|PubMed:7507150, ECO:0000269|PubMed:7508181"
FT                   /id="VAR_003827"
FT   VARIANT         156
FT                   /note="R -> P (in EHK; dbSNP:rs58075662)"
FT                   /evidence="ECO:0000269|PubMed:7507152"
FT                   /id="VAR_003829"
FT   VARIANT         156
FT                   /note="R -> S (in EHK; dbSNP:rs58852768)"
FT                   /evidence="ECO:0000269|PubMed:7507152"
FT                   /id="VAR_003830"
FT   VARIANT         160
FT                   /note="Y -> D (in EHK; severe phenotype; dbSNP:rs58414354)"
FT                   /evidence="ECO:0000269|PubMed:7508181"
FT                   /id="VAR_003831"
FT   VARIANT         160
FT                   /note="Y -> N (in EHK; severe phenotype)"
FT                   /evidence="ECO:0000269|PubMed:7507150"
FT                   /id="VAR_010508"
FT   VARIANT         160
FT                   /note="Y -> S (in EHK; severe phenotype; dbSNP:rs58735429)"
FT                   /evidence="ECO:0000269|PubMed:10201536"
FT                   /id="VAR_010509"
FT   VARIANT         161
FT                   /note="L -> S (in EHK; dbSNP:rs60118264)"
FT                   /evidence="ECO:0000269|PubMed:1380725"
FT                   /id="VAR_003832"
FT   VARIANT         422
FT                   /note="R -> E (in AEI1; requires 2 nucleotide
FT                   substitutions; dbSNP:rs59075499)"
FT                   /evidence="ECO:0000269|PubMed:9036939"
FT                   /id="VAR_033145"
FT   VARIANT         435
FT                   /note="L -> P (in IHL; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:27212473"
FT                   /id="VAR_087806"
FT   VARIANT         439
FT                   /note="K -> E (in EHK; mild phenotype; dbSNP:rs61434181)"
FT                   /evidence="ECO:0000269|PubMed:7512983"
FT                   /id="VAR_010510"
FT   VARIANT         442
FT                   /note="L -> Q (in EHK; dbSNP:rs58026994)"
FT                   /evidence="ECO:0000269|PubMed:7508181"
FT                   /id="VAR_003833"
FT   VARIANT         446
FT                   /note="I -> T (in AEI1; dbSNP:rs62651994)"
FT                   /evidence="ECO:0000269|PubMed:9856845"
FT                   /id="VAR_010511"
FT   VARIANT         449
FT                   /note="Y -> C (in EHK; dbSNP:rs267607383)"
FT                   /evidence="ECO:0000269|PubMed:21271994"
FT                   /id="VAR_071985"
FT   VARIANT         487
FT                   /note="H -> Y (in dbSNP:rs17855579)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:2448602, ECO:0000269|PubMed:2459124,
FT                   ECO:0000269|PubMed:2464696"
FT                   /id="VAR_060723"
FT   CONFLICT        9..11
FT                   /note="KHY -> SKQF (in Ref. 1; AAA60544)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        24..31
FT                   /note="Missing (in Ref. 1; AAA60544)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        86
FT                   /note="R -> H (in Ref. 2; CAA32649)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        106
FT                   /note="S -> N (in Ref. 2; CAA32649)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        181..184
FT                   /note="WYEK -> RYDQ (in Ref. 1; AAA60544)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        189
FT                   /note="H -> R (in Ref. 1; AAA60544)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        197
FT                   /note="S -> G (in Ref. 8; AAA59199)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        266
FT                   /note="K -> Q (in Ref. 1; AAA60544)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        279..280
FT                   /note="EL -> YV (in Ref. 5; AAA59468)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        287
FT                   /note="H -> R (in Ref. 1; AAA60544)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        293
FT                   /note="D -> H (in Ref. 1; AAA60544)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        312
FT                   /note="V -> I (in Ref. 5; AAA59468)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        323
FT                   /note="S -> N (in Ref. 1; AAA60544)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        340
FT                   /note="F -> V (in Ref. 5; AAA59468)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        374
FT                   /note="A -> R (in Ref. 5; AAA59468)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        408
FT                   /note="Q -> H (in Ref. 2; CAA32649)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        420
FT                   /note="Q -> E (in Ref. 1; AAA60544)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        436
FT                   /note="L -> T (in Ref. 1; AAA60544)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        451
FT                   /note="S -> G (in Ref. 8; AAA59199)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        460..461
FT                   /note="GG -> RS (in Ref. 5; AAA59468)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        477
FT                   /note="S -> T (in Ref. 5; AAA59468)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        482
FT                   /note="S -> T (in Ref. 5; AAA59468)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        487..490
FT                   /note="Missing (in Ref. 8; AAA59199)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        491..516
FT                   /note="Missing (in Ref. 1; AAA60544)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        503
FT                   /note="S -> T (in Ref. 5; AAA59468)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        508
FT                   /note="S -> T (in Ref. 5; AAA59468)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        513..519
FT                   /note="YGGGSSS -> LRGELH (in Ref. 5; AAA59468)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        523..527
FT                   /note="GGSSS -> AHST (in Ref. 5; AAA59468)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        524
FT                   /note="G -> GGSSSGGHGG (in Ref. 2; CAA32649)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        534
FT                   /note="S -> N (in Ref. 5; AAA59468)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        535
FT                   /note="S -> F (in Ref. 1; AAA60544)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        542..546
FT                   /note="YGGGS -> LRGRH (in Ref. 5; AAA59468)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        565
FT                   /note="G -> GGYGGGSSSGG (in Ref. 1; AAA60544)"
FT                   /evidence="ECO:0000305"
FT   HELIX           195..295
FT                   /evidence="ECO:0007829|PDB:6E2J"
FT   HELIX           350..454
FT                   /evidence="ECO:0007829|PDB:6UUI"
FT   STRAND          479..481
FT                   /evidence="ECO:0007829|PDB:3ASW"
FT   STRAND          483..486
FT                   /evidence="ECO:0007829|PDB:3ASW"
FT   STRAND          500..508
FT                   /evidence="ECO:0007829|PDB:4F1Z"
SQ   SEQUENCE   584 AA;  58827 MW;  4941ECD2AE46D417 CRC64;
     MSVRYSSSKH YSSSRSGGGG GGGGCGGGGG VSSLRISSSK GSLGGGFSSG GFSGGSFSRG
     SSGGGCFGGS SGGYGGLGGF GGGSFRGSYG SSSFGGSYGG IFGGGSFGGG SFGGGSFGGG
     GFGGGGFGGG FGGGFGGDGG LLSGNEKVTM QNLNDRLASY LDKVRALEES NYELEGKIKE
     WYEKHGNSHQ GEPRDYSKYY KTIDDLKNQI LNLTTDNANI LLQIDNARLA ADDFRLKYEN
     EVALRQSVEA DINGLRRVLD ELTLTKADLE MQIESLTEEL AYLKKNHEEE MKDLRNVSTG
     DVNVEMNAAP GVDLTQLLNN MRSQYEQLAE QNRKDAEAWF NEKSKELTTE IDNNIEQISS
     YKSEITELRR NVQALEIELQ SQLALKQSLE ASLAETEGRY CVQLSQIQAQ ISALEEQLQQ
     IRAETECQNT EYQQLLDIKI RLENEIQTYR SLLEGEGSSG GGGRGGGSFG GGYGGGSSGG
     GSSGGGHGGG HGGSSGGGYG GGSSGGGSSG GGYGGGSSSG GHGGSSSGGY GGGSSGGGGG
     GYGGGSSGGG SSSGGGYGGG SSSGGHKSSS SGSVGESSSK GPRY
//
